Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.47 |
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | KAT7 | O95251 | 1/20 | 0.41 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.41 |
| ▸ | FPR3 | P25089 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605054 | 0.91 | SLC6A2 (0.55) | HTR6BCHEACKR3GPR119SLC6A2 | |
| SCHEMBL3605045 | 0.91 | HTR6 (0.48) | HTR6BCHEACKR3GPR119KDM1A | |
| SCHEMBL4062687 | 0.89 | GPR119 (0.55) | GPR119 | |
| SCHEMBL3616906 | 0.86 | SLC6A2 (0.49) | SLC6A2SLC6A4 | |
| SCHEMBL4063161 | 0.85 | GPR119 (0.52) | GPR119 | |
| SCHEMBL3605040 | 0.83 | SLC6A2 (0.49) | HTR6BCHEACKR3GPR119SLC6A2 | |
| SCHEMBL4059665 | 0.81 | GPR119 (0.53) | HTR6GPR119 | |
| SCHEMBL4064772 | 0.80 | KDM1A (0.42) | GPR119SLC6A2SLC6A4KDM1A | |
| SCHEMBL3616317 | 0.80 | GPR119 (0.43) | ACKR3GPR119 | |
| SCHEMBL4062683 | 0.80 | GPR119 (0.55) | GPR119SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-7601722-B2 | Aryl sulfamide derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | HTR6 21/4885BCHE 686/4885ACKR3 3532/4885 |
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | HTR6 21/4885BCHE 686/4885ACKR3 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.